Pancreatic Cancer Market 2023 Booming in Healthcare | Professional Survey by Pharmacyte Biotech Inc., OncoGenex Pharmaceuticals Inc., Oncolytics Biotech, Etc Players

The Global Pancreatic Cancer Market is growing with the sound pace. According to a recent study report published by the Market Research Future, the Global Pancreatic Cancer Market is booming and expected to gain prominence over the forecast period and is projected to grow a sound pace. The market is projected to demonstrate a sound growth by 2023, surpassing its previous growth records in terms of value with a sound CAGR during the anticipated period (2018-2023). The global Pancreatic Cancer Market is expected to grow at a CAGR of 8.1% during forecasted period 2018-2023.

Global Pancreatic Cancer Market - Overview

Pancreatic Cancer is an enlarged tumor caused by malignant cells in the tissues of the pancreas. The pancreas are organ situated behind the stomach. Pancreatic cancer can be caused by smoking, drinking alcohol, radiotherapy in the past, genetic factors, age, inflammation of the pancreas, obesity, and diabetes mellitus. According to Cancer Research UK, 7 out of 10 cases of chronic pancreatitis are due to heavy drinking habits.

Rising rates in tobacco consumption, increasing cigarette smokers are likely to enhance the growth of pancreatic cancer market. Additionally, rising prevalence of cancer, increase in intake of alcohol, growing obesity rates, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level.

The global pancreatic cancer market is expected to grow at a CAGR of 8.1% during the forecast period 2017-2023.

Get PDF Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/1638

Key Players for Global Pancreatic Cancer Market

Some of key the players in the market are Pharmacyte Biotech Inc. (U.S.), OncoGenex Pharmaceuticals Inc. (U.S.), Oncolytics Biotech (Canada), Diffusion Pharmaceuticals (U.S.), Polaris Pharmaceuticals, Inc. (U.S.), Sun BioPharma, Inc. (U.S.), Midatech Pharma PLC (U.K.), Eli Lilly and Company (U.S.), Celgene Corporation (U.S.), F. Hoffmann-La Roche AG (Switzerland), Amgen, Inc. (U.S.), Novartis International AG (U.S.), Clovis Oncology (U.S.), and others.

Competitive Analysis

Celgene Corporation

Founded in 1980, and headquartered at US, Celgene Corporation is a biopharmaceutical company aimed in the detection and development of treatments for various cancers and inflammatory diseases. Celgene Corporation has its presence all over the world. The firm has focused on various inorganic and organic growth strategies to enhance its services and increase its patient base. For instance in the year 2015, Celgene Corporation received approval from European Commission (EC) for ABRAXANE, a nanotechnology therapy for the treatment of metastatic pancreatic cancer. The firm has been focusing on improving lives of patients with pancreatic cancer. For instance in 2015, Celgene Corporation invested 30% of its revenue on research and development to produce advanced technologies to support patients with pancreatic cancer. By this approval and high research and development expenditure, the firm aims to focus on patient needs and increase its customer base.

Novartis AG

Founded in 1895, and headquartered in Switzerland, Novartis AG is engaged in the manufacture and development of a wide range of healthcare products. In 2016, Novartis and Pfizer collaborated to form a study on tumors driven by mutations in a gene called KRAS that causes cancer. Additionally, in 2017 Novartis and Perthera partnered to support clinical trials for lung cancer patients. This collaboration and partnership enables the firm to widen its foothold in various geographies.

Get an Exclusive Discount on Report @ https://www.marketresearchfuture.com/check-discount/1638

Regional Analysis for Global Pancreatic Cancer Market

Geographically, the pancreatic cancer market is segmented into four key regions: the Americas, Europe, Asia Pacific, and Middle East & Africa.The Americas is further segmented into North America and South America. And North America is segmented into the U.S. and Canada. Globally, the U.S. is the largest market for pancreatic cancer owing to rising prevalence of cancer, increasing consumption of alcohol, increase in per capita R&D spending, along with rise in demand for new and advanced products and techniques. Similarly increasing healthcare spending is likely to grow the demand for pancreatic cancer market. Similarly, according to CMS (Centres for Medicare and Medicaid Services) U.S. health care spending increased 4.3 percent to reach USD 3.3 trillion per person in 2016.For instance, according to National cancer institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S. Similarly, in 2016, U.S. spent over USD 125 billion for cancer care and is expected to spend over USD 156 billion by 2020. According to CDC, around one third of the population is affected with obesity.

Europe accounts for the second largest market due to rising incidence of cancer, growth in research and development to produce advanced technologies, increasing funds, government support and increasing healthcare expenditure. For instance according to Eurostat, Germany spend over EUR 321 billion in the year 2014. Similarly, according to cancer research UK, there were around 9, 921 cases of cancer diagnosed in 2015. This high incidence of cancer is likely to enhance the growth of pancreatic cancer market.

Asia pacific region is expected to be fastest growing region in pancreatic cancer market owing to its growing population and eventually growing patient population. Additionally, increasing healthcare expenditure and growing demand for newer and advanced technologies to treat the growing demand for increasing prevalence of cancer. For instance, US Census Bureau has estimated that by 2050, two third of the world’s older population will reside in Asia.

On the other hand, the Middle East & Africa is expected to witness limited growth due to limited access to the healthcare resources and rising healthcare cost. In the Middle East, the growth of the market is driven by increasing research and development for newer technologies and rising healthcare infrastructure.

Segmentations for Global Pancreatic Cancer Market

The global pancreatic cancer market is segmented on the basis of types, treatment, and end user.

On the basis of the type, it is segmented into endocrine pancreas cancer, exocrine pancreas cancer, and others.

On the basis of the treatment, it is segmented into chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, hormone therapy, and others. Furthermore, the chemotherapy is segmented into antimetabolites, anthracyclines, taxanes, and alkylating agents. The targeted therapy is sub-segmented into tyrosine kinase inhibitors and monoclonal antibodies. And the hormone therapy is sub-segmented into estrogen-receptor modulators, aromatase inhibitors, and others.

On the basis of the end user, it is segmented into hospitals & clinics, research institute, and others.

Do You Have Query? Ask To Our Experts @ https://www.marketresearchfuture.com/enquiry/1638

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Hadapsar, Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.